Axa S.A. Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Axa S.A. decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 80,364 shares of the biopharmaceutical company’s stock after selling 6,413 shares during the period. Axa S.A. owned approximately 0.07% of Regeneron Pharmaceuticals worth $57,246,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Itau Unibanco Holding S.A. increased its stake in shares of Regeneron Pharmaceuticals by 77.9% in the fourth quarter. Itau Unibanco Holding S.A. now owns 153 shares of the biopharmaceutical company’s stock worth $109,000 after acquiring an additional 67 shares during the period. Westbourne Investments Inc. acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter worth about $356,000. Caisse DE Depot ET Placement DU Quebec raised its stake in shares of Regeneron Pharmaceuticals by 59.4% during the 4th quarter. Caisse DE Depot ET Placement DU Quebec now owns 310,153 shares of the biopharmaceutical company’s stock valued at $220,931,000 after buying an additional 115,528 shares during the last quarter. Rehmann Capital Advisory Group lifted its holdings in shares of Regeneron Pharmaceuticals by 26.8% in the 4th quarter. Rehmann Capital Advisory Group now owns 682 shares of the biopharmaceutical company’s stock valued at $487,000 after buying an additional 144 shares during the period. Finally, Triumph Capital Management boosted its stake in shares of Regeneron Pharmaceuticals by 32.4% in the fourth quarter. Triumph Capital Management now owns 560 shares of the biopharmaceutical company’s stock worth $399,000 after buying an additional 137 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Truist Financial decreased their price target on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a “buy” rating for the company in a report on Wednesday. Robert W. Baird lowered their price target on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating on the stock in a report on Friday, April 25th. Bank of America dropped their price target on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating on the stock in a research report on Thursday, April 17th. Guggenheim lowered their target price on shares of Regeneron Pharmaceuticals from $940.00 to $810.00 and set a “buy” rating on the stock in a research note on Thursday. Finally, Royal Bank of Canada cut their price target on Regeneron Pharmaceuticals from $1,051.00 to $943.00 and set an “outperform” rating for the company in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, eighteen have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $892.60.

Regeneron Pharmaceuticals Trading Up 2.6 %

Shares of REGN stock opened at $605.61 on Friday. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a twelve month low of $525.99 and a twelve month high of $1,211.20. The company’s 50-day moving average price is $626.49 and its 200-day moving average price is $709.39. The stock has a market cap of $66.21 billion, a price-to-earnings ratio of 15.82, a PEG ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). The firm had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business’s revenue for the quarter was down 3.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $9.55 earnings per share. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be paid a dividend of $0.88 per share. The ex-dividend date is Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.58%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.